Paolo Fundaro Sells 2,171 Shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) Stock

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) Director Paolo Fundaro sold 2,171 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Friday, March 29th. The stock was sold at an average price of $107.45, for a total value of $233,273.95. Following the transaction, the director now owns 11,114 shares of the company’s stock, valued at $1,194,199.30. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Shares of ICPT opened at $87.38 on Friday. Intercept Pharmaceuticals Inc has a 12-month low of $64.50 and a 12-month high of $133.74. The company has a debt-to-equity ratio of 19.41, a current ratio of 4.22 and a quick ratio of 4.22.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings results on Thursday, February 28th. The biopharmaceutical company reported ($2.97) EPS for the quarter, missing analysts’ consensus estimates of ($2.42) by ($0.55). Intercept Pharmaceuticals had a negative net margin of 172.39% and a negative return on equity of 592.58%. The company had revenue of $53.30 million during the quarter, compared to the consensus estimate of $52.53 million. During the same quarter last year, the firm posted ($4.43) EPS. The company’s quarterly revenue was up 41.4% on a year-over-year basis. Analysts anticipate that Intercept Pharmaceuticals Inc will post -9.13 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC grew its position in shares of Intercept Pharmaceuticals by 3.6% in the 4th quarter. Squarepoint Ops LLC now owns 3,399 shares of the biopharmaceutical company’s stock valued at $343,000 after buying an additional 118 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Intercept Pharmaceuticals by 14.8% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,416 shares of the biopharmaceutical company’s stock valued at $143,000 after purchasing an additional 183 shares in the last quarter. LPL Financial LLC boosted its position in shares of Intercept Pharmaceuticals by 0.3% during the 4th quarter. LPL Financial LLC now owns 74,815 shares of the biopharmaceutical company’s stock valued at $7,541,000 after purchasing an additional 254 shares in the last quarter. Advisor Group Inc. boosted its position in shares of Intercept Pharmaceuticals by 63.5% during the 4th quarter. Advisor Group Inc. now owns 739 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 287 shares in the last quarter. Finally, Strs Ohio boosted its position in shares of Intercept Pharmaceuticals by 30.0% during the 4th quarter. Strs Ohio now owns 1,300 shares of the biopharmaceutical company’s stock valued at $131,000 after purchasing an additional 300 shares in the last quarter. Hedge funds and other institutional investors own 70.24% of the company’s stock.

Several analysts recently issued reports on ICPT shares. Zacks Investment Research upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $97.00 price target for the company in a research note on Monday, December 31st. Raymond James restated a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Thursday, February 14th. Laidlaw upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price target for the company from $99.00 to $130.00 in a research note on Monday, January 14th. Jefferies Financial Group lifted their price objective on Intercept Pharmaceuticals to $150.00 and gave the company a “buy” rating in a report on Monday, January 28th. Finally, Needham & Company LLC raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $150.00 price objective for the company in a report on Thursday, January 24th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and sixteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $144.05.

WARNING: “Paolo Fundaro Sells 2,171 Shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) Stock” was first reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://www.baseballdailydigest.com/news/2019/04/21/insider-selling-intercept-pharmaceuticals-inc-icpt-director-sells-2171-shares-of-stock.html.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.

Featured Article: Current Ratio

Insider Buying and Selling by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.